Hironobu Endo

Dr. Hironobu Endo

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2024 in Neuron
Verified
Journal Article
Open access
HEHironobu Endo
Hironobu Endo
MOMaiko Ono
Maiko Ono
YTYuhei Takado
Yuhei Takado
KMKiwamu Matsuoka
Kiwamu Matsuoka
MTManami Takahashi
Manami Takahashi
MHMakoto Higuchi
Makoto Higuchi
Deposition of α-synuclein fibrils is implicated in Parkinson's disease (PD) and dementia with Lewy bodies (DLB), while in vivo detection of α-synuclein pathologies in these illnesses has been challenging. Here, we have developed a small-molecule ligand, C05-05, for visualizing α-synuclein deposits in the brains of living subjects. In vivo optical and positron emission tomography (PET) imaging of mouse and marmoset models demonstrated that C05-05 captured a dynamic propagation of fibrillogenesis along neural pathways, followed by disruptions of these structures. High-affinity binding of 18F-C05-05 to α-synuclein aggregates in human brain tissues was also proven by in vitro assays. Notably, PET-detectable 18F-C05-05 signals were intensified in the midbrains of PD and DLB patients as compared with healthy controls, providing the first demonstration of visualizing α-synuclein pathologies in these illnesses. Collectively, we propose a new imaging technology offering neuropathology-based translational assessments of PD and allied disorders toward diagnostic and therapeutic research and development.

30 August 2022 in Movement Disorders
Verified
Journal Article
Open access
KMKiwamu Matsuoka
Kiwamu Matsuoka
MOMaiko Ono
Maiko Ono
YTYuhei Takado
Yuhei Takado
KHKosei Hirata
Kosei Hirata
HEHironobu Endo
Hironobu Endo
MHMakoto Higuchi
Makoto Higuchi

28 August 2022 in Movement Disorders
Verified
Journal Article
Open access
HEHironobu Endo
Hironobu Endo
KTKenji Tagai
Kenji Tagai
MOMaiko Ono
Maiko Ono
YIYoko Ikoma
Yoko Ikoma
AOAsaka Oyama
Asaka Oyama
MHMakoto Higuchi
Makoto Higuchi
Background: We recently developed a positron emission tomography (PET) probe, [18F]PM‐PBB3, to detect tau lesions in diverse tauopathies, including mixed three‐repeat and four‐repeat (3R + 4R) tau fibrils in Alzheimer's disease (AD) and 4R tau aggregates in progressive supranuclear palsy (PSP). For wider availability of this technology for clinical settings, bias‐free quantitative evaluation of tau images without a priori disease information is needed.Objective: We aimed to establish tau PET pathology indices to characterize PSP and AD using a machine learning approach and test their validity and tracer capabilities.Methods: Data were obtained from 50 healthy control subjects, 46 patients with PSP Richardson syndrome, and 37 patients on the AD continuum. Tau PET data from 114 regions of interest were subjected to Elastic Net cross‐validation linear classification analysis with a one‐versus‐the‐rest multiclass strategy to obtain a linear function that discriminates diseases by maximizing the area under the receiver operating characteristic curve. We defined PSP‐ and AD‐tau scores for each participant as values of the functions optimized for differentiating PSP (4R) and AD (3R + 4R), respectively, from others.Results: The discriminatory ability of PSP‐ and AD‐tau scores assessed as the area under the receiver operating characteristic curve was 0.98 and 1.00, respectively. PSP‐tau scores correlated with the PSP rating scale in patients with PSP, and AD‐tau scores correlated with Mini‐Mental State Examination scores in healthy control–AD continuum patients. The globus pallidus and amygdala were highlighted as regions with high weight coefficients for determining PSP‐ and AD‐tau scores, respectively.Conclusions: These findings highlight our technology's unbiased capability to identify topologies of 3R + 4R versus 4R tau deposits. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society

11 August 2025 in Nature Reviews Neurology
Verified
Journal Article
Closed access
MHMakoto Higuchi
Makoto Higuchi
KTKenji Tagai
Kenji Tagai
KTKeisuke Takahata
Keisuke Takahata
HEHironobu Endo
Hironobu Endo

13 March 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
RGRyoji Goto
Ryoji Goto
KMKiwamu Matsuoka
Kiwamu Matsuoka
YKYasuyuki Kimura
Yasuyuki Kimura
YKYuko Kataoka
Yuko Kataoka
MOMasaki Oya
Masaki Oya
HEHironobu Endo
Hironobu Endo
18F-SPAL-T-06 and 18F-C05-05 are two novel positron emission tomography (PET) radioligands targeting α-synuclein fibrils. Our study aimed to evaluate the biodistribution, safety, and radiation dosimetry of each tracer in humans. Biodistribution and radiation dosimetry studies were carried out with two healthy volunteers for each tracer, 18F-SPAL-T-06 (one female and one male volunteer, both aged 63 years) and 18F-C05-05 (one female and one male volunteer, aged 63 and 73 years, respectively). After injection of either tracer, dynamic PET images were acquired from head to upper thigh. Effective dose of each tracer was estimated using OLINDA/EXM Version 2.2. Injection of either of the tracers caused no adverse effects. Greatest uptake of both tracers was observed in the liver and small intestine. The estimated absorbed doses were highest in the biliary tract, followed by the lower large intestinal wall. Effective doses were 35.9 µSv/MBq for 18F-SPAL-T-06 and 30.5 µSv/MBq for 18F-C05-05. 18F-SPAL-T-06 and 18F-C05-05 are safe for in vivo PET imaging of humans. Their mean effective doses were 6.6 mSv for 18F-SPAL-T-06 and 5.6 mSv for 18F-C05-05 when 185 MBq of either tracer was given to a subject, and they were comparable to other amyloid and tau PET tracers labelled with 18F. Trial registration Trial registration number: jRCTs031210180, Registered date: 2nd July 2021 (18F-SPAL-T-06) https://jrct.niph.go.jp/en-latest-detail/jRCTs031210180 and Trial registration number: jRCTs031220123, Registered date: 9th June 2022 (18F-C05-05) https://jrct.niph.go.jp/en-latest-detail/jRCTs031220123.

19 January 2026 in Brain Sciences
Verified
Journal Article
Open access
PDF file
Roberto CiliaRoberto Cilia
Roberto Cilia
Dario ArnaldiDario Arnaldi
Dario Arnaldi
Bénédicte BallangerBénédicte Ballanger
Bénédicte Ballanger
RCRoberto Ceravolo
Roberto Ceravolo
RMRosa De Micco
Rosa De Micco
TEThilo Van Eimeren
Thilo Van Eimeren
The “Neuroimaging and Pathology Biomarkers in Parkinson’s Disease” course held on 12–13 September 2025 in Milan, Italy, convened an international faculty to review state-of-the-art biomarkers spanning neurotransmitter dysfunction, protein pathology and clinical translation. Here, we synthesize the four themed sessions and highlights convergent messages for diagnosis, stratification and trial design. The first session focused on neuroimaging markers of neurotransmitter dysfunction, highlighting how positron emission tomography (PET), single photon emission computed tomography (SPECT), and magnetic resonance imaging (MRI) provided complementary insights into dopaminergic, noradrenergic, cholinergic and serotonergic dysfunction. The second session addressed in vivo imaging of protein pathology, presenting recent advances in PET ligands targeting α-synuclein, progress in four-repeat tau imaging for progressive supranuclear palsy and corticobasal syndromes, and the prognostic relevance of amyloid imaging in the context of mixed pathologies. Imaging of neuroinflammation captures inflammatory processes in vivo and helps study pathophysiological effects. The third session bridged pathology and disease mechanisms, covering the biology of α-synuclein and emerging therapeutic strategies, the clinical potential of seed amplification assays and skin biopsy, the impact of co-pathologies on disease expression, and the “brain-first” versus “body-first” model of pathological spread. Finally, the fourth session addressed disease progression and clinical translation, focusing on imaging predictors of phenoconversion from prodromal to clinically overt stages of synucleinopathies, concepts of neural reserve and compensation, imaging correlates of cognitive impairment, and MRI approaches for atypical parkinsonism. Biomarker-informed pharmacological, infusion-based, and surgical strategies, including network-guided and adaptive deep brain stimulation, were discussed as examples of how multimodal biomarkers may inform personalized management. Across all sessions, the need for harmonization, longitudinal validation, and pathology-confirmed outcome measures was consistently emphasized as essential for advancing biomarker qualification in multicentre research and clinical practice.